Quarterly report pursuant to Section 13 or 15(d)

Notes Payable (Narrative) (Details)

v3.2.0.727
Notes Payable (Narrative) (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
May. 31, 2015
USD ($)
Jun. 30, 2015
USD ($)
$ / shares
Jun. 30, 2014
USD ($)
Jun. 30, 2015
USD ($)
day
$ / shares
Jun. 30, 2014
USD ($)
May. 15, 2015
USD ($)
Dec. 31, 2014
USD ($)
Mar. 31, 2014
USD ($)
$ / shares
shares
Debt Instrument [Line Items]                
Unamortized debt discount   $ 0   $ 0     $ 863,813  
Gains (Losses) on Extinguishment of Debt   (2,440,714) $ 0 (2,440,714) $ (2,610,196)      
Proceeds from notes payable       54,500,000 30,000,000      
Change in fair value of financial instruments   (1,852,730) (92,332) (125,627) 300,151      
Interest expense   1,600,000 914,000 2,500,000 1,900,000      
Interest expense recorded related to amortization   146,000 195,000 359,000 437,000      
Debt Instrument, increase in accrued interest   429,000   $ 429,000        
Capital Royalty Group                
Debt Instrument [Line Items]                
Debt face amount           $ 50,000,000    
Debt Instrument, unused borrowing capacity           10,000,000    
Payment terms       2 years        
Notes payable   50,300,000   $ 50,300,000        
Debt Instrument, Fee Amount           625,000    
Debt unamortized discount, Net           2,200,000    
Unamortized debt discount   2,200,000   2,200,000        
End-of-term fee   1,000,000   1,000,000   1,000,000    
EBITDA, less than       5,000,000        
Lymphoseek sales revenue, less than       $ 11,000,000        
Target revenue minimum           45,000,000    
Cure right ratio       2.5        
Liquidity minimum           $ 5,000,000    
Debt Instrument, increase in accrued interest   255,000            
Capital Royalty Group | Debt Instrument, Redemption, Period One [Member]                
Debt Instrument [Line Items]                
Early payment percentage       5.00%        
Capital Royalty Group | Debt Instrument, Redemption, Period Two [Member]                
Debt Instrument [Line Items]                
Early payment percentage       1.00%        
Capital Royalty Group | Debt Instrument, Redemption, Period Three [Member]                
Debt Instrument [Line Items]                
Early payment percentage       0.00%        
Capital Royalty Group | Interest Option, Cash [Member]                
Debt Instrument [Line Items]                
Debt instrument, interest rate           14.00%    
Capital Royalty Group | Interest Option, Combination Cash and Paid-in-kind [Member]                
Debt Instrument [Line Items]                
Debt Instrument, interest rate, paid in cash           10.00%    
Debt Instrument, Interest rate, paid-in-kind           4.00%    
Oxford Finance, LLC                
Debt Instrument [Line Items]                
Debt face amount               $ 30,000,000
Debt instrument, interest rate               8.50%
Repayments of debt $ 31,600,000              
Notes payable           $ 26,900,000    
Early redemption fee           289,000    
End-of-term fee     2,400,000   2,400,000 2,400,000    
Gains (Losses) on Extinguishment of Debt $ 2,400,000              
Oxford Finance, LLC | Series KK warrants                
Debt Instrument [Line Items]                
Number of shares underlying warrant issued | shares               391,032
Exercise price of warrant issued, dollars per share | $ / shares               $ 1.918
Platinum Credit Facility [Member]                
Debt Instrument [Line Items]                
Notes payable   7,900,000   $ 7,900,000        
Convertible threshold trading days | day       10        
Threshold consecutive trading days       10 days        
Share price trigger | $ / shares       $ 2.53        
Line of credit, current           7,700,000    
Maximum borrowing capacity, amount   $ 50,000,000   $ 50,000,000   $ 35,000,000    
Effective interest rate   14.125%   14.125%        
Convertible threshold percentage of stock price trigger       90.00%        
Proceeds from notes payable       $ 4,500,000        
Conversion option fair value   $ 2,500,000   2,500,000        
Change in fair value of financial instruments   1,900,000 $ 96,000 126,000 $ (298,000)      
Estimated fair value   10,400,000   10,400,000        
Unused borrowing capacity   27,300,000   27,300,000        
Unused additional borrowing capacity   15,000,000   $ 15,000,000        
Debt Instrument, increase in accrued interest   174,000            
Platinum Credit Facility [Member] | Prime Rate [Member]                
Debt Instrument [Line Items]                
Debt Instrument, basis spread on variable rate       6.75%        
Platinum Credit Facility [Member] | Interest Rate Pursuant to CGR Term Loan [Member]                
Debt Instrument [Line Items]                
Debt Instrument, basis spread on variable rate       0.125%        
R-NAV                
Debt Instrument [Line Items]                
Notes payable   $ 666,666   $ 666,666        
Debt Instrument, principal payment       $ 333,333        
Minimum                
Debt Instrument [Line Items]                
Exercise price of warrant issued, dollars per share | $ / shares   $ 1.918   $ 1.918        
Minimum | Platinum Credit Facility [Member]                
Debt Instrument [Line Items]                
Debt instrument, interest rate   10.00%   10.00%